Purpose: Substance use disorders (SUD) are an important health issue internationally. Traditional outpatient programmes often do not adequately address the substantial medical and social needs and in addition many patients have difficulties accessing the care needed. The assertive community treatment (ACT) model was originally developed for patients with a severe mental illness but has been adapted for patients with SUD by integrating specific SUD treatments into the traditional ACT model. This paper aims to assess the effectiveness of ACT for patients with SUD on a number of measures. Methods: We performed a systematic review of ACT interventions for patients with SUD by analyzing randomized controlled studies published before June 2017 found on the electronic databases PsychINFO, MEDLINE, PsychARTICLES. Eleven publications using 5 datasets were included in the analysis. Quality of studies was analyzed using the JADAD scale or Oxford quality scoring system. Outcome measures used were substance use, treatment engagement, hospitalization rates, quality of life, housing status, medication compliance and legal problems. Patients included in the studies had a diagnosis of SUD. Two datasets included homeless patients and 2 datasets included patients with high service use. Results and Conclusions: The results of the very few existing randomized control studies are mixed. Treatment engagement was higher for ACT in 4 datasets. One dataset reported higher service contact rates for the ACT group than for controls. In 2 datasets a positive effect on hospitalization rates was found. Higher fidelity to the ACT model appears to improve outcomes. Substance use reduced only in half of the datasets, of which only one showed a significant reduction in the ACT group. Overall, ACT is a promising approach that may be useful for promoting treatment engagement for patients with SUD. According to earlier studies on patients with severe mental illness, patients with high inpatient service use benefit most from this assertive approach. We hypothesize that a similar high need user group among patients with SUD might benefit most from ACT. Further research is needed to examine which types of clinical interventions might help difficult-to-engage patients with addictions.

Journal Section:
Editor's choice
Keywords:
Addiction, Assertive community treatment, Out-patient treatment, Recovery, Substance use disorders
1.
Degenhardt L, Hall W: Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012; 379: 55–70.
2.
Cuffel BJ: Comorbid substance use disorder: prevalence, patterns of use, and course. New Dir Ment Health Serv 1996; 70: 93–105.
3.
Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK: Comorbidity of mental disorders with alcohol and other drug abuse. Results from the epidemiologic catchment area (ECA) study. JAMA 1990; 264: 2511–2518.
4.
Kessler RC, Nelson CB, McGonagle KA, Edlund MJ, Frank RG, Leaf PJ: The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. Am J Orthopsychiatry 1996; 66: 17–31.
5.
Kessler RC, Crum RM, Warner LA, Nelson CB, Schulenberg J, Anthony JC: Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the national comorbidity survey. Arch Gen Psychiatry 1997; 54: 313–321.
6.
Warner LA, Kessler RC, Hughes M, Anthony JC, Nelson CB: Prevalence and correlates of drug use and dependence in the United States. Results from the national comorbidity survey. Arch Gen Psychiatr 1995; 52: 219–229.
7.
Slade T, McEvoy PM, Chapman C, Grove R, Teesson M: Onset and temporal sequencing of lifetime anxiety, mood and substance use disorders in the general population. Epidemiol Psychiatr Sci 2015; 24: 45–53.
8.
Young JT, Heffernan E, Borschmann R, Ogloff JRP, Spittal MJ, Kouyoumdjian FG, Preen DB, Butler A, Brophy L, Crilly J, Kinner SA: Dual diagnosis of mental illness and substance use disorder and injury in adults recently released from prison: a prospective cohort study. Lancet Public Health 2018; 5:e237–e248.
9.
Kessler RC: The epidemiology of dual diagnosis. Biol Psychiatry 2004; 56: 730–737.
10.
Ziedonis D, Brady K: Dual diagnosis in primary care. Detecting and treating both the addiction and mental illness. Med Clin North Am 1997; 81: 1017–1036.
11.
Thornton LK, Baker AL, Lewin TJ, Kay-Lambkin FJ, Kavanagh D, Richmond R, Kelly B, Johnson MP: Reasons for substance use among people with mental disorders. Addict Behav 2012; 37: 427–434.
12.
Hagnell O, Gräsbeck A: Comorbidity of anxiety and depression in the Lundby 25-year prospective study: the pattern of subsequent episodes, 1990.
13.
Murphy JM: Diagnostic Comorbidity and Symptom Co-Occurrence: The Stirling County Study, 1990.
14.
Margolese HC, Malchy L, Negrete JC, Tempier R, Gill K: Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophr Res 2004; 67: 157–166.
15.
Brady TM, Krebs CP, Laird G: Psychiatric comorbidity and not completing jail-based substance abuse treatment. Am J Addict 2004; 13: 83–101.
16.
Curran GM, Sullivan G, Williams K, Han X, Allee E, Kotrla KJ: The association of psychiatric comorbidity and use of the emergency department among persons with substance use disorders: an observational cohort study. BMC Emerg Med 2008; 8: 17.
17.
Curran GM, Sullivan G, Williams K, Han X, Collins K, Keys J, Kotrla KJ: Emergency department use of persons with comorbid psychiatric and substance abuse disorders. Ann Emerg Med 2003; 41: 659–667.
18.
Ngamini-Ngui A, Fleury MJ, Moisan J, Grégoire JP, Lesage A, Vanasse A: High users of emergency departments in Quebec among patients with both schizophrenia and a substance use disorder. Psychiatr Serv 2014; 65: 1389–1391.
19.
Gindi RM, Cohen RA, Kirzinger WK: Emergency room use among adults aged 18–64: Early release of estimates from the National Health Interview Survey, January–June 2011. National Center for Health Statistics. May 2012. Available from: http://www.cdc.gov/nchs/nhis/releases.htm.
20.
Bhalla IP, Stefanovics EA, Rosenheck RA: Clinical epidemiology of single versus multiple substance use disorders: polysubstance use disorder. Med Care 2017; 55:S24–S32.
21.
Pines JM, Asplin BR, Kaji AH, Lowe RA, Magid DJ, Raven M, Weber EJ, Yealy DM: Frequent users of emergency department services: gaps in knowledge and a proposed research agenda. Acad Emerg Med 2011; 18.
22.
Khan S: Concurrent mental and substance use disorders in Canada. Health Rep 2017; 28: 3–8.
23.
Raven MC, Carrier ER, Lee J, Billings JC, Marr M, Gourevitch MN: Substance use treatment barriers for patients with frequent hospital admissions. J Subst Abuse Treat 2010; 38: 22–30.
24.
Miller W, Rollnick S: Motivational Interviewing: Preparing People to Change Addictive Behavior, New York, Guilford press google scholar, 1991.
25.
Marlatt GA, Gordon JR: Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviors, New York, Guilford press, 1985.
26.
Khan R, Khazaal Y, Thorens G, Zullino D, Uchtenhagen A: Understanding swiss drug policy change and the introduction of heroin maintenance treatment. Eur Addict Res 2014; 20: 200–207.
27.
Nordt C, Vogel M, Dey M, Moldovanyi A, Beck T, Berthel T, Walter M, Seifritz E, Dürsteler KM, Herdener M: One size does not fit all-evolution of opioid agonist treatments in a naturalistic setting over 23 years. Addiction 2019; 114: 103–111.
28.
Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, Kim MM, Shanahan E, Gass CE, Rowe CJ, Garbutt JC: Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA 2014; 311: 1889–1900.
29.
McGovern MP, Lambert-Harris C, Gotham HJ, Claus RE, Xie H: Dual diagnosis capability in mental health and addiction treatment services: an assessment of programs across multiple state systems. Adm Policy Ment Health 2014; 41: 205–214.
30.
Andersson HW, Steinsbekk A, Walderhaug E, Otterholt E, Nordfjærn T: Predictors of dropout from inpatient substance use treatment: a prospective cohort study. Subst Abuse 2018; 12.
31.
Brorson HH, Arnevik EA, Rand-Hendriksen K, Duckert F: Drop-out from addiction treatment: a systematic review of risk factors. Clin Psychol Rev 2013; 33: 1010–1024.
32.
Pringle JL, Emptage NP, Hubbard RL: Unmet needs for comprehensive services in outpatient addiction treatment. J Subst Abuse Treat 2006; 30: 183–189.
33.
Han B, Compton WM, Blanco C, Colpe LJ: Prevalence, treatment, and unmet treatment needs Of US adults with mental health and substance use disorders. Health Aff (Millwood) 2017; 36: 1739–1747.
34.
Salyers MP, Tsemberis S: ACT and recovery: Integrating evidence-based practice and recovery orientation on assertive community treatment teams. Community Ment Health J 2007; 43: 619–641.
35.
Hogan MF: The president’s new freedom commission: recommendations to transform mental health care in America. Psychiatr Serv 2003; 54: 1467–1474.
36.
Stein LI, Test MA: Alternative to mental hospital treatment. I. Conceptual model, treatment program, and clinical evaluation. Arch Gen Psychiatry 1980; 37: 392–397.
37.
Bond GR, Drake RE, Mueser KT, and Latimer E: Assertive community treatment for people with severe mental illness. Dis Manag Health Outcomes 2001; 9: 141–159.
38.
Bond GR, Drake RE: The critical ingredients of assertive community treatment. World Psychiatry 2015; 14: 240–242.
39.
Burns BJ, Santos AB: Assertive community treatment: an update of randomized trials. Psychiatr Serv 1995; 46: 669–675.
40.
Burns T, CattyJ, Dash M, Roberts C, Lockwood A, Marshall M: Use of intensive case management to reduce time in hospital in people with severe mental illness: systematic review and meta-regression. BMJ 2007; 335: 336.
41.
Bonsack C, Adam L, Haefliger T, Besson J, Conus P: Difficult-to-engage patients: a specific target for time-limited assertive outreach in a Swiss setting. Can J Psychiatry 2005; 50: 845–850.
42.
Lambert M, Bock T, Schöttle D, Golks D, Meister K, Rietschel L, Bussopulos A, Frieling M, Schödlbauer M, Burlon M: Assertive community treatment as part of integrated care versus standard care: a 12-month trial in patients with first-and multiple-episode schizophrenia spectrum disorders treated with quetiapine immediate release (ACCESS trial). J Clin Psychiatry 2010; 71: 1313–1323.
43.
Test MA, Wallisch LS, Allness DJ, Ripp K: Substance use in young adults with schizophrenic disorders. Schizophr Bull 1989; 15: 465–476.
44.
Marshall M, Lockwood A: Assertive community treatment for people with severe mental disorders. Cochrane Database Syst Rev 2000: CD001089.
45.
Bertelsen M, Jeppesen P, Petersen L, Thorup A, Øhlenschlæger J, le Quach P, Christensen TØ, Krarup G, Jørgensen P, Nordentoft M: Five-year follow-up of a randomized multicenter trial of intensive early intervention vs standard treatment for patients with a first episode of psychotic illness: the OPUS trial. Arch Gen Psychiatry.2008: 65: 762–771.
46.
Nordentoft M, Rasmussen JØ, Melau M, Hjorthøj CR, Thorup A: How successful are first episode programs? A review of the evidence for specialized assertive early intervention. Curr Opin Psychiatry. 2014; 27: 167–172.
47.
http://www.prisma-statement.org/documents/PRISMA%20IPD%20checklist.pdf.
48.
Essock SM, Mueser KT, Drake RE, Covell NH, McHugo GJ, Frisman LK, Kontos NJ, Jackson CT, Townsend F, Swain K: Comparison of ACT and standard case management for delivering integrated treatment for co-occurring disorders. Psychiatr Serv 2006; 57: 185–196.
49.
Frisman LK, Mueser KT, Covell NH, Lin HJ, Crocker A, Drake RE, Essock SM: Use of integrated dual disorder treatment via assertive community treatment versus clinical case management for persons with co-occurring disorders and antisocial personality disorder. J Nerv Ment Dis 2009; 197: 822–828.
50.
Manuel JI, Covell NH, Jackson CT, Essock SM: Does assertive community treatment increase medication adherence for people with co-occurring psychotic and substance use disorders? J Am Psychiatri Nurses Assoc 2011; 17: 51–56.
51.
Morse GA, Calsyn RJ, Klinkenberg WD, Helminiak TW, Wolff N, Drake RE, Yonker RD, Lama G, Lemming MR, McCudden S: Treating homeless clients with severe mental illness and substance use disorders: costs and outcomes. Community Ment Health J 2006; 42: 377–404.
52.
Calsyn RJ, Yonker RD, Lemming MR, Morse GA, Klinkenberg WD: Impact of assertive community treatment and client characteristics on criminal justice outcomes in dual disorder homeless individuals. Crim Behav Ment Health 2005; 15: 236–248.
53.
Lemming MR: Client outcomes and the working alliance in assertive community treatment programs. Care Manag J 2004; 5: 199–202.
54.
Drake RE, McHugo GJ, Clark RE, Teague GB, Xie H, Miles K, Ackerson TH: Assertive community treatment for patients with co-occurring severe mental illness and substance use disorder: a clinical trial. Am J Orthopsychiatry 1998; 68: 201–215.
55.
McHugo GJ, Drake RE, Teague GB, Xie H: Fidelity to assertive community treatment and client outcomes in the New Hampshire dual disorders study. Psychiatr Serv 1999; 50: 818–824.
56.
Clark RE, Teague GB, Ricketts SK, Bush PW, Xie H, McGuire TG, Drake RE, McHugo GJ, Keller AM, Zubkoff M: Cost-effectiveness of assertive community treatment versus standard case management for persons with co-occurring severe mental illness and substance use disorders. Health Serv Res 1998; 33: 1285–1308.
57.
Bond GR, McDonel EC, Miller LD, Pensec M: Assertive community treatment and reference groups: an evaluation of their effectiveness for young adults with serious mental illness and substance abuse problems. Psychiatr Rehabil J 1991; 15: 31–43.
58.
Drummond C, Gilburt H, Burns T, Copello A, Crawford M, Day E, Deluca P, Godfrey C, Parrott S, Rose A: Assertive community treatment for people with alcohol dependence: a pilot randomized controlled trial. Alcohol Alcohol.2017; 52: 234–241.
59.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996; 17: 1–2.
60.
Cunningham J, Calsyn RJ, Burger GK, Morse GA, Klinkenberg WD: Client outcomes and the working alliance in the client-case manager relationship: a causal analysis. Care Manag J 2007; 8: 106–112.
61.
Miller W: National Institutes of Health, National Institute on Alcohol Abuse, and Alcoholism, Form 90: A Structured Assessment Interview for Drinking and Related Behaviors: Test Manual: US Department of Health and Human Services, 1996.
62.
Skinner HA, Allen BA: Alcohol dependence syndrome: measurement and validation. 1982; 91: 199–209.
63.
Svanum S, Schladenhauffen J: Lifetime and recent alcohol consumption among male alcoholics. Neuropsychological implications. J Nerv Ment Dis 1986; 174: 214–220.
64.
Wanberg KW, Horn JL, Foster FM: A differential assessment model for alcoholism. The scales of the alcohol use inventory. J Stud Alcohol 1977; 38: 512–543.
65.
Bond GR, Miller LD, Krumwied RD, Ward RS: Assertive case management in three CMHCs: a controlled study. Hosp Community Psychiatry 1988; 39: 411–418.
66.
Lukoff D, Nuechterlein K, Ventura J: Manual for the expanded brief psychiatric rating scale. Schizophr Bull 1986; 12: 594–602.
67.
Tracey TJ, Kokotovic AM: Factor structure of the working alliance inventory. J Consult Clin Psychol 1989; 1: 207–210.
68.
McLellan AT, Luborsky L, Woody GE, O’Brien CP: An improved diagnostic evaluation instrument for substance abuse patients. The addiction severity index. J Nerv Ment Dis 1980; 168: 26–33.
69.
Drake RE, Mercer-McFadden C: Assessment of Substance Use among Persons with Chronic Mental Illnesses, 1995.
70.
McHugo GJ, Drake RE, Burton HL, Ackerson TH: A scale for assessing the stage of substance abuse treatment in persons with severe mental illness. J Nerv Ment Dis 1995; 183: 762–777.
71.
Lehman AF: A quality of life interview for the chronically mentally ill. Eval Program Plann 1988; 11: 51–62.
72.
Latimer EA: Economic impacts of assertive community treatment: a review of the literature. Can J Psychiatry 1999; 44: 443–454.
73.
DiClemente CC, Crisafulli MA: Alcohol relapse and change needs a broader view than counting drinks. Alcohol Clin Exp Res 2017; 41: 266–269.
74.
Maisto SA, Roos CR, Hallgren KA, Moskal D, Wilson AD, Witkiewitz K: Do alcohol relapse episodes during treatment predict long-term outcomes? Investigating the validity of existing definitions of alcohol use disorder relapse. Alcohol Clin Exp Res 2016; 40: 2180–2189.
75.
Kiluk BD, Fitzmaurice GM, Strain EC, Weiss RD: What defines a clinically meaningful outcome in the treatment of substance use disorders: reductions in direct consequences of drug use or improvement in overall functioning? Addiction 2019; 114: 9–15.
76.
Nef F, Philippot P, Verhofstadt L: L’approche processuelle en évaluation et intervention cliniques : une approche psychologique intégrée. Revue Francophone de Clinique Cognitive et Comportementale 2012; 17: 23.
© 2019 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2019
You do not currently have access to this content.